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Abstract. Commercial chikungunya virus (CHIKV)–specific IgM detection kits were evaluated at the Centers for
Disease Control and Prevention (CDC), the Public Health Agency of Canada National Microbiology Laboratory,
and the Caribbean Public Health Agency (CARPHA). The Euroimmun Anti-CHIKV IgM ELISA kit had ≥ 95%
concordance with all three reference laboratory results. The limit of detection for low CHIK IgM+ samples, as mea-
sured by serial dilution of seven sera up to 1:12,800 ranged from 1:800 to 1:3,200. The Euroimmun IIFT kit evaluated
at CDC and CARPHA performed well, but required more retesting of equivocal results. The InBios CHIKjj Detect
MAC-ELISA had 100% and 98% concordance with CDC and CARPHA results, respectively, and had equal sensitiv-
ity to the CDC MAC-ELISA to 1:12,800 dilution in serially diluted samples. The Abcam Anti-CHIKV IgM ELISA
had high performance at CARPHA, but at CDC, performance was inconsistent between lots. After replacement of
the biotinylated IgM antibody controls with serum containing CHIKV-specific IgM and additional quality assurance/
control measures, the Abcam kit was rereleased and reevaluated at CDC. The reformatted Abcam kit had 97%
concordance with CDC results and limit of detection of 1:800 to 1:3,200. Two rapid tests and three other CHIKV
MAC-ELISAs evaluated at CDC had low sensitivity, as the CDC CHIKV IgM in-house positive controls were below
the level of detection. In conclusion, laboratories have options for CHIKV serological diagnosis using validated
commercial kits.
INTRODUCTION
Chikungunya virus (CHIKV) is an arthropod-borne alpha-
virus that causes acute epidemic polyarthralgia and febrile
illness.1–4 Since 2004, CHIKV has reemerged in Africa,
Asia, and Oceania, resulting in millions of human infec-
tions.1,5–7 In the fall of 2013, local transmission of CHIKV
was reported on Saint Martin Island in the Caribbean.8,9
Since then the virus has disseminated rapidly throughout
the Americas.10 In the United States, dengue (DEN) and
CHIK became reportable diseases in January 2010 and Janu-
ary 2015, respectively.
Clinical illness is characterized by acute onset of joint
pain, followed by myalgia, rash, and fever.3 Patients usually
recover within a week, although some patients report long-
term arthralgia. Dengue viruses (DENVs) co-circulate in many
of the regions where CHIKV has emerged, and clinical symp-
toms between the two diseases are similar.11,12 Laboratory-
based diagnosis is essential to differentiate CHIKV from DENV
infections, as the clinical care of the patients may be different.13
The primary laboratory test used to diagnose CHIKV infec-
tion in serum collected within the first 5 days after onset is
detection of CHIKV or viral RNA, after which the CHIKV-
specific IgM antibody-capture enzyme-linked immunosorbent
assay (MAC-ELISA) is a sensitive test.14 There are a vari-
ety of commercially available CHIKV IgM detection assays,
but assessments of their performance have been limited.15–20
Comprehensive evaluations of the commercial assays were
needed to harmonize results, assess assay performance, and
provide recommendations for their use. The assessments were
done in three laboratories: the U.S. Centers for Disease Con-
trol and Prevention (CDC) Arboviral Diseases Branch, the
Public Health Agency of Canada National Microbiology Lab-
oratory (NML), and the Caribbean Public Health Agency
(CARPHA). All nine of the commercially available kits were
evaluated at CDC with a panel of well-characterized archived
diagnostic sera (Table 1). NML evaluated the Euroimmun
Anti-CHIKV IgM ELISA with samples submitted for diag-
nostic testing from Canadian travelers who had recently vis-
ited CHIKV-endemic areas. Comparative testing with the
Euroimmun, Abcam, and InBios CHIKV MAC-ELISA kits
and the Euroimmun CHIK IgM indirect immunofluorescent
test (IIFT) was done at CARPHA with selected samples from
patients and controls from different CARPHA member states
in the Caribbean, which had initially been tested at CDC.
MATERIALS AND METHODS
CDC evaluation. CDC samples. A panel of serum sam-
ples without personal identifiers was selected from the CDC
Arboviral Diseases Branch collection of archived diagnostic
specimens. Reference testing had been performed at CDC
according to the following algorithm. Samples that had been
collected < 6 days after onset of illness were tested by real-
time reverse transcription polymerase chain reaction (RT-
PCR) using two sets of primers and probes designed by R. S.




GTA + ACGAGTCATCTGCGTATTGGGACGCA). A pos-
itive result with both sets of primers/probes was considered
confirmatory, and the samples were not tested further. Those
with negative results and samples collected ≥ 6 days after ill-
ness onset were tested by the CDC in-house MAC-ELISA.21
Samples were diluted 1:400 and run according to standard
operating procedures (SOPs) in triplicate, against viral and
normal antigens.21 Samples with positive and equivocal (EQ)
ELISA results were confirmed by CHIKV 90% serum dilu-
tion endpoint plaque reduction neutralization assay (PRNT)
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in Vero cells using a 0.5% agarose double overlay, with 0.005%
neutral red in the second overlay, applied after 2 days of
incubation.22,23 CHIKV strain S27 was used as the challenge
virus. The lower level of quantitation was 1:10 dilution. The
CDC test results were considered CHIK IgM positive or neg-
ative. The original panel was composed of 92 samples that had
all been tested by CDC CHIKV MAC-ELISA: 46 samples
positive for CHIKV IgM from outbreaks of CHIKV Asian
strain in Yap (2013) and the Caribbean (2014) and travelers to
the Philippines; four pooled samples of CHIKV IgM in-house
positive controls (IHPCs) with low, medium, and high positive-
to-negative ratios (P/N) (CDC P/N approximately 4.5, 10, and
20, respectively) from outbreaks of CHKV East/Central/South
African strain in Comoros (2005) and India (2006); 36 samples
negative for CHIKV and other arbovirus IgM, from patients
with fever from Thailand, Yap, and the Caribbean; and six
IgM IHPCs for DEN (N = 2), o’nyong-nyong (ONN), Mayaro
(MAY), Venezuelan equine encephalitis (VEE), and North
American eastern equine encephalitis (EEE) viruses. The
MAYV and ONNV IgM IHPCs had positive results by CDC
CHIKV MAC-ELISA and were considered CDC CHIK IgM+
(cross-reactive), but had been confirmed as CHIK negative by
PRNT. Samples were coded CHIKV IgM+ or CHIKV IgM−.
In the CDC MAC-ELISA, the calculated P/N is not a quantita-
tive unit: P/N < 2 is negative, P/N 2–3 is EQ, and P/N > 3 is
positive.21 However, samples were chosen so that there was a
range of P/N ratios represented: approximately 30% P/N 3–5
(low positives), 40% with P/N 5–10, and 30% with P/N > 10.
The number of days from onset of illness to sample collection
ranged from 2 to 33. Samples with similar results were added
as volumes were depleted. All samples were labeled using a
code that was devoid of personal identifiers. Because of this
testing algorithm, there were no samples in the panel that had
positive results by real-time RT-PCR, which had been subse-
quently tested by the CDC CHIK MAC-ELISA.
CDC test methods. The samples in the reference panel had
previously been tested in the CDC diagnostic laboratory,
and CDC results were considered the reference standard.
The CDC uses the same ELISA format for testing all arbovi-
ruses, with previously optimized sample dilutions of 1:400.24
Although the sensitivity and specificity of the CDC MAC-
ELISA has not been determined for each arbovirus, the
assay was shown to have sensitivity and specificity of 91%
and 90%, respectively, for West Nile virus when samples with
EQ results were confirmed by PRNT.25,26 All kit manufac-
turers or distributors were contacted by CDC about the eval-
uations, and kits used in the evaluations were either donated
by the suppliers or purchased by CDC. Results of the evalu-
ations were reported to the manufacturer of each kit, and all
manufacturers were afforded the opportunity to modify the
kits and resubmit them for reevaluation. All kits were stored
as prescribed by the manufacturer. The samples were diluted
and tests were run according to the manufacturers’ instruc-
tions in the kit insert. Because reference panel sample vol-
umes were limited, each kit was initially tested with a subset
of 8–10 samples which included a CHIKV IHPC and normal
(CHIKV IgM− control, IHNC) serum. If the results of the
IHPC and IHNC were correct, the rest of the samples in the
panel were tested. The kit results were classified as CHIKV
IgM+, CHIKV IgM−, or EQ according to the cutoff values
provided by the manufacturer. EQ results were retested.
Results that remained EQ after retesting were coded as neg-
ative. Replicate testing was not routinely undertaken, as this
would not typically be done in the diagnostic laboratory, with
the following exceptions. In the Abcam kit standard proto-
col, antigen was incubated in the plate for 30 minutes at
room temperature. In the troubleshooting section of the
instructions, there was a suggestion to incubate the antigen
overnight at 4°C if there was low signal. Samples were tested
by both methods. Samples were also retested with different
TABLE 1
Characteristics of nine commercial CHIK IgM detection assays







20 samples (hours) Storage conditions (°C) Evaluated by laboratory
Microplate MAC-ELISA
Abcam (Cambridge, UK) Anti-CHIKV IgM
human ELISA
91 10 4 2–8 CARPHA, CDC
CTK Biotech (San Diego, CA) Recombilisa CHIK
IgM Test
91 10 2 2–8 CDC
Euroimmun (Luebeck, Germany) Anti-CHIKV
ELISA (IgM)
93 2 3.5 2–8 CARPHA, CDC,
and NML
Genway (San Diego, CA) CHIKV IgM
μ-capture ELISA
91 10 4 2–8 CDC
InBios (Seattle, WA) CHIKjj Detect
MAC-ELISA






CHIKa IgM ELISA 91 10 2 2–8 CDC
Rapid test
CTK Biotech On-site CHIK IgM
Combo Rapid test
30 30 0.5 2–30 CDC
SD Diagnostics SD BIOLINE
Chikungunya IgM




50 ∼15 3 2–8 CARPHA, CDC
CARPHA = Caribbean Public Health Agency; CDC = Centers for Disease Control and Prevention; CHIKV = chikungunya virus; IIFT = indirect immunofluorescent test; MAC-ELISA =
IgM antibody-capture enzyme-linked immunosorbent assay; NML = the Public Health Agency of Canada National Microbiology Laboratory.
*Immunosorb IgG depletion sample buffer purchased separately.
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lots of the Abcam and Euroimmun ELISA kits. In addition,
after initial testing by the Euroimmun, Abcam, and InBios
kits, samples with discordant results were retested by both
the CHIKV CDC MAC-ELISA and kit, and any samples
with CDC results that changed after retesting were excluded
from the evaluation.
To test sensitivities of the kits, one CDC CHIKV IHPC
and six CDC CHIKV IgM+ samples were diluted 2-fold to
1:12,800 in sample dilution buffer and tested. According to
the instructions in the Euroimmun ELISA kit, samples were
incubated for 10 minutes in the sample dilution buffer, as it
contains antihuman IgG antibodies that bind the IgG in the
sample. To control for differences in results due to the incu-
bation step, samples tested by the Euroimmun ELISA were
prepared by diluting before and after incubation in the sam-
ple dilution buffer, and both dilution series were tested.
NML evaluation. NML samples. A total of 247 serum sam-
ples were selected for the Euroimmun IgM kit evaluation;
100 previously confirmed CHIKV IgM+ diagnostic serum sam-
ples, 99 diagnostic samples determined to be CHIK IgM−
but harboring pathogen-specific antibodies (IgM and/or IgG)
against a number of other human pathogens, and 48 clinical
samples that had been shown to be CHIKV IgM− and with
no recorded positive serological results for other infectious
agents (Tables 2 and 3). Of the 100 confirmed CHIKV IgM+
serum samples, 63 were collected from suspected cases of
CHIK with travel history to the Caribbean and other endemic
areas in the Americas; two each had travel history to Asia,
Africa, and Oceania. However, 31 CHIKV IgM+ sera cases
had no travel history information (Table 2).
Serum samples selected for Euroimmun Anti-CHIKV
ELISA kit evaluations were previously tested by an in-house
CHIKV MAC-ELISA based on the CDC MAC-ELISA
method described above, with the exceptions that sam-
ples were tested in duplicate and the assay used tissue
culture–derived antigen produced at NML.21 Samples that
generated CHIKV IgM+ results were further tested by PRNT
and/or real-time RT-PCR and/or, for the purposes of this
study, hemagglutination inhibition assay (HAI) to confirm
clinical cases (Table 2). The PRNT was performed as the
gold standard confirmatory assay essentially as described
above using CHIK strain S27 as the challenge virus, with the
exception that the second overlay was applied at approxi-
mately 3 days.22
The real-time RT-PCR assay was added to confirm any
samples that were CHIKV IgM+ but had a negative result in
the PRNT as well as to determine the number of CHIKV
viremic individuals returning to Canada. In the real-time RT-
PCR testing, viral RNA was extracted from clinical samples
using the Qiagen QIAamp Viral RNA mini kit (Hilden,
Germany) according to manufacturer’s protocol. Amplifica-
tion was performed on a Vii A 7 (Applied Biosystems, Foster
City, CA) using the TaqMan Fast Virus 1 Step Master Mix
(Life Technologies, Carlsbad, CA) according to manufac-
turer’s protocol. Viral extracts were tested by two singleplex
reactions using two sets of primers and probes, one described
by Pongsiri and others27 and the other designed by R. S.
Lanciotti at CDC (see above section “CDC samples”). Sam-
ples that generated Ct values of < 38 in both singleplex reac-
tions were classified as reactive. For the purposes of this
project, an HAI assay was used for supplemental confirmatory
testing using suckling mouse brain antigen produced at NML
according to the protocol of Beaty and others.22,28
The 100 NML CHIKV IgM+ samples exhibited a range of
P/N values: 21 samples exhibited low positive values (P/N: 3–4.9),
28 samples demonstrated moderate positive values (P/N: 5–9.9),
and 51 samples generated high P/N values (P/N ≥ 10).
NML test methods. Samples were tested twice in separate
runs in the Euroimmun IgM ELISA as per manufacturer’s
instructions. If there was disparity between replicate results,
TABLE 2
Serological and travel history characteristics of serum samples used





Number of samples tested 100 147
Serology
Confirmed by PRNT only 54 0
Confirmed by real-time RT-PCR only 10 0
Confirmed by HAI only 13 0
Confirmed by both PRNT and HAI 17 0
Confirmed by both real-time
RT-PCR and HAI
3 0
Confirmed by both PRNT and
real-time RT-PCR
2 0




Travel to Americas‡ 63 31
Travel to Asia 2 4
Travel to Africa 2 1
Travel to Oceania 2 0
No travel history provided 31 111
CHIKV = chikungunya virus; ELISA = enzyme-linked immunosorbent assay; HAI =
hemagglutination inhibition assay; PRNT = plaque reduction neutralization assay; NML =
the Public Health Agency of Canada National Microbiology Laboratory; RT-PCR = reverse
transcription polymerase chain reaction.
*Serum samples were classified as originating from confirmed cases of CHIKV infection if
CHIK IgM+ and either PRNT and/or real-time RT-PCR and/or HAI positive. Samples were
identified as either CHIKV IgM+ or IgM− using an in-house CDC-based IgM ELISA.
†See Table 3 for description of sample panel with no detectable CHIK IgM antibodies.
‡South America, Central America, or the Caribbean; two CHIKV IgM samples with travel
history to Mexico were also included.
TABLE 3
Serum sample panel used at NML for determining specificity of the
Euroimmun IgM ELISA kit (N = 147)
Pathogen-specific antibody detected
(IgM and/or IgG)
No. tested by Euroimmun




Hepatitis B virus 3
Hepatitis C virus 3
Herpes simplex virus 3
Human immunodeficiency virus 3
Japanese encephalitis virus 3
Jamestown Canyon virus 3
Parvovirus 13
Ross River virus 3
Varicella zoster virus 3
West Nile virus 4







No pathogen-specific antibody detected* 48
ELISA = enzyme-linked immunosorbent assay; NML = the Public Health Agency of
Canada National Microbiology Laboratory.
*Serum samples for which there were no recorded positive results for any specific anti-
bodies to other agents.
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samples were run a third time and the two concordant results
were averaged and used for data analysis.
CARPHA evaluation. CARPHA samples. Samples used
in the panel were representatives from CARPHA-associated
islands. Aliquots of samples had been previously referred to
CDC during the outbreak of CHIK in the Caribbean in early
2014, as there were no characterized in-house controls that could
be used for diagnostic testing. CDC results were considered the
reference standard for the evaluation. All samples were labeled
using a code that was devoid of personal identifiers. In addition,
a set of samples predating the outbreak was used for assessing
cross-reactivity (N = 12), which were positive at CARPHA for
DEN (N = 4), cytomegalovirus (CMV) (N = 2), Epstein–Barr
virus (EBV) (N = 2), hepatitis A virus (HAV) (N = 2), and
leptospirosis (N = 2); as these samples were not tested at CDC,
results were not included for calculation of accuracy, sensi-
tivity, and specificity.
CARPHA test methods. Abcam, InBios, and Euroimmun
ELISA kits and the Euroimmun IIFA (IgM) kit were stored
and run as prescribed by manufacturer’s instructions with the
exception of overnight incubation with Abcam antigen for
approximately 16–18 hours at 4°C. Because of limited avail-
able quantity of sera, subsets of 36, 27, 21, and 26 samples
considered CHIKV IgM+ by CDC and 10, 14, 12, and 10 sam-
ples considered IgM− by CDC were used for evaluating the
Abcam, InBios, Euroimmun IIFA, and Euroimmun ELISA
kits, respectively. To evaluate within-run and between-run
variances, a set of samples was tested in duplicate in the same
plate as well as tested in a second run. Furthermore, an alter-
nate kit lot number was used to evaluate Abcam and InBios
between-lot variance.
Statistical methods. For the purposes of this evaluation, test
results were considered in two categories, CHIKV IgM+ and
CHIKV IgM−. EQ results from test kits were coded negative
for analysis. Sensitivity was defined as the proportion of sam-
ples with a reference standard result of CHIKV IgM+ that
had a CHIKV IgM+ result in the test kit. Specificity was
defined as the percentage of reference standard CHIKV IgM−
results that had CHIKV IgM− results in the kit. Accuracy was
defined as the agreement of results between the evaluated kit
and the reference standard assay. The 95% confidence inter-
vals (CIs) for proportions were calculated according to the
efficient-score method, corrected for continuity based on the
procedure outlined by Wilson.29,30
RESULTS
The Euroimmun ELISA was evaluated at CDC, NML,
and CARPHA; the Abcam and InBios ELISA kits and the
Euroimmun IIFT were evaluated at CDC and CARPHA; and
the CTK, Genway, and SD Diagnostics ELISA kits and the
CTK and SD BIOLINE CHIKV IgM rapid tests were eval-
uated only at CDC. Characteristics of the sample sizes and
specimen type and the test results are shown in the corre-
sponding tables: CDC (Table 4), NML (Tables 2 and 3), and
CARPHA (Table 5). The summary results of the evaluations
from all three laboratories for the four kits with the highest
performance are shown in Table 6.
CDC evaluations. Nine CHIKV IgM detection assays were
assessed at CDC with a panel of serum specimens that had
previously been submitted to and tested at the CDC arbovi-
rus diagnostic laboratory (Table 1). CDC results and final
interpretations were considered the reference standard. Sam-
ples were tested by the commercial IgM detection assays
listed according to manufacturers’ instructions. Test runs were
considered valid or invalid according to the criteria in the
SOP; only valid test results are reported here. A CDC
CHIKV IHPC was included in every run. At the end of the
evaluation, samples with discordant results were retested by
the CDC CHIKV MAC-ELISA. If the CDC results changed
between initial diagnostic testing and retesting, the sample was
excluded from the evaluation panel.
ELISA kits. Of the samples, 20 were tested by the CTK
ELISA. Of the 16 CDC CHIKV IgM+ samples, two had a
positive result in the CTK ELISA; the CDC CHIKV IHPC
had a negative result (Table 4, Figure 1). The Genway
ELISA was initially evaluated with 43 samples, 27 CDC IgM+
and 16 CDC IgM−. None of the CDC CHIKV IgM+ samples,
including the CDC CHIKV IHPC, tested in two replicates,
had a positive result in the Genway ELISA kit (Table 4,
Figure 1). The SD ELISA was evaluated with 44 samples.
Of the 31 CDC CHIKV IgM+ samples, 12 were positive by
the SD ELISA, including the CDC CHIKV IHPC; two of
the 13 CDC CHIKV IgM− samples were positive by the SD
ELISA. These three assays had sensitivities of < 50% and
therefore were not further evaluated.
Results of the Abcam ELISA with a subset of samples
were > 90% concordant with CDC results (data not shown).
The rest of the panel was then tested in duplicate in two runs
according to the SOP, with an antigen incubation time of
30 minutes at room temperature, and alternately, overnight
at 4°C (Table 4). Of the 48 CDC CHIK IgM+ samples, 44
and 47 were positive by the Abcam test with 30 minutes and
overnight antigen incubations, resulting in sensitivities of 92%
(95% CI: 79–97%) and 98% (95% CI: 88–100%), respec-
tively. Performance indicators of the test with 30 minutes anti-
gen incubation are shown in Figure 1 (lot no. GR166537-2).
Of the 42 CDC CHIKV IgM− samples, three and one had
EQ results (coded as negative) in the Abcam assay incubated
30 minutes or overnight, respectively, and had specificities of
95% (95% CI: 83–99%) and 98% (95% CI: 86–100%),
respectively. One sample with an EQ result in the CDC
ELISA with no neutralizing antibody titer was classified as
CDC CHIKV IgM−. This sample had a positive result in the
Abcam assay under both antigen incubation conditions. The
CDC ONNV IHPC had a negative result in the Abcam assay;
the MAYV IHPC was not included in this initial testing. The
DENV IHPC with the CDC CHIKV IgM+ result had a nega-
tive and positive result in the Abcam test with the antigen
incubated 30 minutes and overnight, respectively. Accuracy
of the Abcam kit, therefore, was 93% (95% CI: 86–97%)
with 30 minutes antigen incubation and 98% (95% CI: 91–
100%) with overnight antigen incubation. However, approx-
imately 4 months later, an Abcam kit with a different lot
number (GR183899-4) was purchased and none of the CDC
CHIKV IHPCs or IgM+ samples tested with the new lot kit
had a positive result (Figures 1 and 2), including samples that
previously had been tested with the Abcam kit and had cor-
rect results. To investigate the cause of the difference in per-
formance between the two kit lots, reagents from the first lots
of kits received were swapped one by one with reagents
from the newest lot. The assay worked as expected when the
biotinylated antibody from the new lot was replaced with bio-
tinylated antibody from the old lot, indicating lot-to-lot
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variability in the activity of the biotinylated antibody. It was
notable that, throughout all these runs, the optical densities
(ODs) of the kit positive and cutoff controls were in the valid
range, despite the negative result for the IHPCs with the new
lot kits and even if no antigen or biotinylated antibody was
added to the control wells (lot no. GR183899-4; Figure 2).
Abcam was notified of the poor performance of the newer lot
kits, and the nonspecific reactivity of the controls. As a result,
the kit components were modified as follows. The kit cutoff and
positive controls were replaced with CHIKV IgM−specific
human serum, and the concentration of the biotinylated anti-
body was adjusted to increase sensitivity with a validation
panel of low positive samples with ODs just above the cutoff.
Because of the substantial changes made to the kit components,
TABLE 5
Summary results of four CHIKV IgM detection assays evaluated at CARPHA
Test Kit result CDC CHIKV ELISA IgM+ CDC CHIKV ELISA IgM− Total
Euroimmun ELISA + 26 0 26
− 0 10 10
Total 26 10 36
Euroimmun IIFT + 21 1 22
− 0 11 11
Total 21 12 33
Abcam ELISA (4°C incubation) + 36 0 36
− 0 10 10
Total 36 10 46
InBios ELISA + 27 1 28
− 0 13 13
Total 27 14 41
CARPHA = Caribbean Public Health Agency; CDC = Centers for Disease Control and Prevention; CHIKV = chikungunya virus; ELISA = enzyme-linked immunosorbent assay; IIFT = indi-
rect immunofluorescent test.
TABLE 4
Summary results of nine CHIKV IgM detection assays evaluated at CDC
Test Kit result CDC CHIKV IgM+* CDC CHIKV IgM−† Total
CTK Recombilisa CHIK IgM Test + 2 0 2
− 14 4 18
Total 16 4 20
Genway CHIKV IgM μ-capture ELISA + 0 0 0
− 27 16 43
Total 27 16 43
SD Diagnostics CHIKa IgM ELISA + 12 2 14
− 19 11 30
Total 31 13 44
Abcam Anti-CHIKV IgM human ELISA (30 minutes 25°C incubation),
lot no. GR166537-2
+ 44 2 46
− 3 37 40
EQ 1 3 4
Total 48 42 90
Abcam ELISA (ON 4°C incubation), lot no. GR166537-2 + 47 1 48
− 1 40 41
EQ 0 1 1
Total 48 42 90
Abcam ELISA (30 minutes 25°C incubation), lot no. GR232915-1 + 36 1 37
− 0 32 32
EQ 0 1 1
Total 36 34 70
Euroimmun Anti-CHIKV ELISA (IgM) + 51 1 52
− 1 38 39
EQ 0 1 1
Total 52 40 92
InBios CHIKjj Detect MAC-ELISA + 36 0 36
− 0 35 35
Total 36 35 71
CTK On-site CHIK IgM Combo RT + 3 0 3
− 20 4 24
Total 23 4 27
SD BIOLINE Chikungunya IgM + 0 0 0
− 24 7 31
Total 24 7 31
Euroimmun Anti-CHIKV IIFT (IgM) + 34 0 34
− 3 35 38
EQ 0 3 3
Total 37 38 75
CARPHA = Caribbean Public Health Agency; CDC = Centers for Disease Control and Prevention; CHIKV = chikungunya virus; EQ = equivocal; MAC-ELISA = IgM antibody capture
enzyme-linked immunoassay; IIFT = indirect immunofluorescence test; ON = overnight; RT = rapid test.
*Includes Mayaro and o’nyong-nyong viruses IgM PC serum.
†Includes Venezuelan equine encephalitis and North American eastern equine encephalitis viruses IgM PC serum.
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the performance indicators of the initial evaluation described
above were invalidated, and the revised kits needed to be
reevaluated. Abcam sent three lots of the revised kits to CDC,
one (lot no. GR232915-1) of which was used to test a panel of
70 samples (Table 4, Figures 1 and 2). The other two lots were
evaluated with a subset of samples and had equivalent results.
Coding the EQ result as NEG, the revised Abcam ELISA had
sensitivity of 100% (95% CI: 88–100%), specificity of 97%
(95% CI: 83–100%), and overall agreement of 99% (95% CI:
91–100%). The MAYV and ONNV IHPC had positive results
in both the CDC and Abcam tests.
Results of the Euroimmun ELISA with a subset of samples
were 100% concordant with CDC results (data not shown);
therefore the rest of the panel of 92 specimens was tested in
two runs. Of the 52 CDC CHIKV IgM+ samples, 51 were
positive by Euroimmun ELISA (sensitivity 98%; 95% CI: 88–
100%); 38 of the 40 CDC CHIKV IgM− samples had a nega-
tive result and one had a EQ result (coded as negative) in the
Euroimmun ELISA (specificity 97.5%; 95% CI: 85–100%)
(Table 4, Figure 1). Accuracy of the Euroimmun kit with CDC
results was 98% (95% CI: 92–100%). The MAYVand ONNV
IHPC had positive results, similar to the CDC results. A subset
TABLE 6
Summary of the Euroimmun, InBios, and Abcam CHIK MAC-ELISAs and Euroimmun IIFT evaluations at CARPHA, CDC, and NML
Reference laboratory (no. of samples tested) % Sensitivity (95% CI) % Specificity (95% CI) Accuracy (95% CI)
Abcam ELISA*
CDC (N = 68) 100 (88–100) 97 (82–100) 99 (91–100)
Euroimmun ELISA
CARPHA (N = 36) 100 (84–100) 100 (66–100) 100 (88–100)
CDC (N = 68) 100 (88–100) 97 (82–100) 99 (91–100)
NML (N = 247) 94 (87–98) 96 (91–98) 95 (91–97)
Euroimmun IIFT
CARPHA (N = 33) 100 (81–100) 92 (60–100) 97 (82–100)
CDC (N = 75) 92 (77–98) 100 (89–100) 96 (88–99)
InBios ELISA
CARPHA (N = 41) 100 (84–100) 93 (64–100) 98 (86–100)
CDC (N = 68) 100 (88–100) 100 (87–100) 100 (93–100)
CARPHA = Caribbean Public Health Agency; CDC = Centers for Disease Control and Prevention; CHIK = chikungunya; CI = confidence interval; IIFT = indirect immunofluorescent test;
MAC-ELISA = IgM antibody-capture enzyme-linked immunosorbent assay; NML = the Public Health Agency of Canada National Microbiology Laboratory.
*Revised kit. CARPHA evaluation of the Abcam kit not included, as the kit components were modified after the evaluation, invalidating the results.
FIGURE 1. Performance of CHIKV IgM detection assays compared with CDC results as the reference standard. *CDC CHIKV IHPC had
negative result in test. **CDC CHIKV IHPC had positive result in test. CDC = Centers for Disease Control and Prevention; CHIKV =
chikungunya virus; IHPC = in-house positive control; ND = not done; RT = rapid test.
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of samples was retested with a Euroimmun kit from a differ-
ent lot, and the results were equivalent (data not shown).
The InBios CHIK MAC-ELISAwas evaluated with 71 sam-
ples, as there was not sufficient volume remaining to test the
complete original panel (Table 4, Figure 1). The results were
100% concordant (95% CI: 94–100%) with CDC results,
including positive results with the ONNVand MAYV IHPCs,
and therefore had 100% sensitivity and specificity (95% CI:
88–100%).
Rapid tests. The CTK rapid test was evaluated with a sub-
set of 27 samples in two runs. Of the 23 CDC CHIKV IgM+
samples tested, three were positive by the CTK rapid test,
but the CDC CHIKV IHPC had a negative result (Table 4,
Figure 1). Thirty-one samples were tested in the SD rapid test
in two runs. None of the 24 CDC CHIKV IgM+ samples,
including the CDC CHIKV IHPC, had a positive result in
the SD rapid test (Table 4, Figure 1). Neither of these two
rapid tests was evaluated further.
IFA. A subset of 16 samples initially was tested with the
Euroimmun CHIKV IgM IIFT; results of 15 samples had
concordant results. The rest of the panel of 75 samples was
tested in two sequential runs. Of the 44 samples tested in the
first run, eight samples with EQ (N = 4), weak positive, or
invalid (N = 4) results from the first run were retested in
the second run. After the second run, six samples needed
retesting, three with EQ results and three CDC CHIKV
IgM+ samples that had discordant results between the first
and second run. Because there was insufficient volume for
retesting, the EQ samples were not retested per the testing
algorithm and coded as negative. Of the 37 CDC CHIKV
IgM+ samples tested, 34 had positive results in the Euroimmun
IIFT (sensitivity 92%; 95% CI: 77–98%) (Table 4, Figure 1).
Three of the 38 CDC CHIKV IgM− samples that had EQ
results were coded as negative, resulting in 100% specificity
(95% CI: 89–100%). Overall accuracy of the Euroimmun
IIFT kit was 96% (95% CI: 88–99%).
Comparison of performance between the CDC, Euroimmun,
InBios, and Abcam ELISA.Kit evaluations were done sequen-
tially, and because of the limited sample volume and retesting
needed, all kits were not evaluated with identical samples. To
compare performance between the kits, the results of 68 sam-
ples (35 CDC CHIKV IgM+, 33 CHIKV IgM−) that had
been tested in the Euroimmun, InBios, and revised Abcam
ELISAs were used (Table 6). Results were 100% concor-
dant between the CDC and the InBios ELISA and 99%
concordant between the CDC and the revised Abcam and
the Euroimmun ELISAs (Table 6).
Serum titration. The CDC CHIKV IHPC and six CDC
CHIKV IgM+ samples from the Caribbean were diluted 2-fold
from 1:100 to 1:12,800 and tested in the CDC, Euroimmun,
InBios, and revised Abcam ELISAs. Sensitivities of the kits
compared with the CDC MAC-ELISA are shown in Figure 3.
CHIKV IgM was detectable by the CDC and InBios assays to
the highest dilution, whereas the endpoint of detection ranged
from 1:800 in sample 5 in both the Euroimmun and Abcam
assays, to 1:3,200 and 1:6,400, respectively, in sample 2.
NML evaluations. Of the 100 samples that tested IgM+ in
the NML in-house CHIKV MAC-ELISA, 94 generated posi-
tive IgM results on the Euroimmun EIA (Table 2). Four
samples had EQ results in the Euroimmun ELISA, of which
three had been confirmed by CHIK real-time RT-PCR and
one by PRNT. Two CHIKV IgM+ samples, which had been
confirmed by real-time RT-PCR, had negative results in the
Euroimmun ELISA. Among the 147 CHIKV IgM− samples
tested, two parvovirus IgM+ and four Anaplasma IgG+ samples
generated Euroimmun IgM+ results (Table 3). Overall the
FIGURE 2. Abcam CHIK MAC-ELISA performance assessment with CDC CHIKV IHPC, by lot number. CDC = Centers for Disease Con-
trol and Prevention; CHIKV = chikungunya virus; IHPC = in-house positive control.
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Euroimmun assay had 95% accuracy (95% CI: 91–97%),
94% sensitivity (95% CI: 87–98%), and 96% specificity (CI:
91–98%) at NML (Table 6).
CARPHA evaluations. Four CHIKV IgM detection assays
were evaluated: the Abcam, Euroimmun, and InBios MAC-
ELISAs and the Euroimmun IIFT (Table 5). Results of the
testing at CDC were considered the reference standard. Accu-
racy of the Euroimmun ELISA (N = 36) was 100% (95% CI:
88–100%), with 100% sensitivity (26/26; 95% CI: 84–100%)
and specificity (10/10; 95% CI: 66–100%). Within-run variance
was 100% concordant (25/25), although a slight decrease in
OD was observed for samples placed in later wells. Between-
run variance (different plates with similar lot number) was
100% concordant (8/8). In the second run, the OD increased
in most of the samples, although there was no change in the
overall results. The only difference between the runs was an
approximately 2 minute longer incubation period (from a total
of 1 hour) in the second run.
Evaluation of Euroimmun IIFT for IgM detection (N = 33)
showed 97% accuracy (95% CI: 82–100%), between CDC
results and results achieved at CARPHA. Sensitivity was 100%
(95% CI: 81–100%) and specificity was 92% (95% CI: 60–
100%). Discordance occurred with false-positive results for
one CDC IgM− sample. Evaluation of between-run and within-
run variances showed 100% concordance (33/33). Because the
IIFT requires a person to score the result based on their obser-
vations of the fluorescence of the cells under the microscope,
a between-reader variance was evaluated. Results from an
experienced reader were 100% concordant with CDC results
(45/45), whereas results by a reader with no previous experi-
ence in IFA were 91% (41/45) concordant. Of note was the
non-florescent green background seen with some samples,
which could prove a difficulty for users new to IFA. This
background was minimized with the use of an Evans blue
counter stain commonly used at CARPHA with IFA. Slides
originally washed with water distilled at CARPHA showed
some background; however, this water had a pH of < 6.2.
After replacement with commercially distilled water (pH 7.0),
the background was reduced.
The Abcam ELISA kit had 100% accuracy (N = 46; 95%
CI: 90–100%), sensitivity (36/36; 95% CI: 88–100%), and
specificity (10/10; 95% CI: 66–100%) compared with CDC
results. Within-run variance was 96% (24/25), and a general
decrease in OD for samples placed in later wells was observed.
Between-run variance evaluated by three runs was 100%
concordant (19/19). Testing was performed with an approx-
imate 16–18 hours overnight antigen incubation. The second
run incubation was half an hour longer than first and third
run and as expected, lead to a general increase in OD. Over-
all concordance of between-lot variance was 94% (16/17),
as one sample was negative with one lot and inconclusive
with a second lot. Moreover, the average ODs with the
second lot were lower than with the first. An increase in the
OD value of the blank well with the second lot was noted.
However, raw OD values were also lower. Modifications were
made to the Abcam kit after the CARPHA evaluation; these
results are not valid for the kit in its current format and there-
fore are not included in summary (Table 6).
Overall concordance of the InBios kits (N = 41) with CDC
results was 98% (95% CI: 86–100%), with 100% (27/27)
sensitivity (95% CI: 84–100%) and 93% (13/14) specificity
(95% CI: 64–100%). Within-run variance was 100% concor-
dant (40/40) with overall OD correlation between wells > 0.998.
Between-run variances with the same kit lot evaluated three
times were 100% concordant (N = 40). Between-lot variances
were found to be 98% concordant (46/47). Overall OD values
with the second lot were slightly lower than the first lot.
The Euroimmun, InBios and Abcam ELISA kits showed
no cross-reactivity with sera positive for anti-DEN, anti-CMV,
anti-EBV, anti-HAV, and anti-Leptospira IgM antibodies. One
sample positive for leptospirosis also had a positive result in
the Euroimmun IIFT.
DISCUSSION
CHIKV, which reemerged in Asia and Oceania beginning
in 2004 and emerged in the Americas in 2013, has caused large
outbreaks, resulting in large numbers of serological samples
submitted to diagnostic laboratories for testing (http://www
.paho.org/hq/index.php?option=com_topics&view=article&id=
343&Itemid=40931). The projected expansion and endemic-
ity of CHIKV is likely, and laboratories will need to build
and maintain high-volume diagnostic testing capacity in the
future. Validated and reliable commercial CHIKV diagnos-
tic assays are essential for these laboratories. CHIKV IgM
detection assays are available commercially in various for-
mats, including plate-based ELISAs, IIFT slides, and rapid
tests. Assessments of these kits were conducted in three dif-
ferent diagnostic laboratory settings.
The CDC arbovirus diagnostic laboratory receives samples
for reference diagnostic testing from outbreaks and from
U.S. travelers to regions where CHIKV is circulating. Thus
the evaluation panel was composed of confirmed, archived
diagnostic samples. At NML, the Health Agency of Canada
Arbovirus Reference and Diagnostic Laboratory, requests for
CHIK testing in travelers has gone from 50 to 200 annually to
1,926 in 2014 and > 2,000 in the first 6 months of 2015. Most
of the samples did not have accompanying information about
the dates of illness onset or sample collection, or in some
cases, travel history. The Euroimmun ELISA was evaluated
with samples previously tested with NML in-house assays and
which were predominately collected from individuals who had
traveled to the Caribbean. In the NML testing algorithm, all
samples were first tested by MAC-ELISA. Samples with IgM+
results were confirmed by a combination of real-time RT-PCR,
FIGURE 3. Comparison of sensitivity by serum titration.
Chikungunya virus (CHIKV) IgM+ samples from the Caribbean
were diluted 2-fold to 1:12,800 in sample dilution buffer. The revised
Abcam kit with CHIKV-specific IgM serum controls was used for
the evaluation.
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PRNT, and for the purposes of this study, HAI. Interestingly, of
the 100 CHIKV IgM+ samples, CHIKV RNAwas also detected
in 16 samples by real-time RT-PCR. Unfortunately, without infor-
mation on the timing of the sample collection, no conclusions
can be made about duration of viremia and immune response.
The third part of the evaluations were conducted at
CARPHA, which is in the consortium of 26 member states
of the English-speaking Caribbean islands and Haiti, Belize,
Surinam, Guyana, Aruba, Curacao, Sint Maarten, and the BES
islands. In late 2013, CARPHA began to receive specimens
from the British Virgin Islands and Dominica for CHIKV diag-
nostic testing. Sample aliquots were initially sent to CDC for
testing until CARPHAwas able to implement testing. By the
end of 2014, CARPHA had received approximately 4,500 sam-
ples from 19 CARPHA member states for CHIKV testing.
Of the 3,000 samples tested, 54% were CHIKV positive. Ini-
tially, CDC ELISA reagents were supplied to CARPHA,
but like other laboratories in the region, CARPHAwill likely
receive a large number of samples for the near future and will
need to use a validated commercial assay to test them. A set
of samples with results reported from CDC were selected to
evaluate the Euroimmun, InBios, and Abcam ELISAs and
Euroimmun IIFT kits at CARPHA. This provided an oppor-
tunity to assess the performance of the kits in a separate labo-
ratory from CDC, where the initial testing had been done.
The Euroimmun ELISA was the only assay evaluated in
all three laboratories. Accuracy was high, at 99%, 95%, and
100% for samples tested at CDC, NML, and CARPHA,
respectively (Table 6). Sensitivity of the Euroimmun ELISA
for low positive samples was measured by serially diluting
seven CHIKV IgM+ samples from 1:100 to 12,800 (Figure 3).
Compared with CDC testing, in which CHIKV IgM was
detectable in all samples up to the final dilution, the end-
point of detection in the Euroimmun ELISA kit ranged from
1:800 to 1:3,200. At CARPHA, results of replicate testing
to measure within-run and between-run variances were 100%
concordant with CDC results, with some decrease in OD
observed for samples located in later wells.
The Abcam Anti-CHIKV IgM human ELISA kit was
evaluated at CDC and CARPHA. Two lots evaluated at
CARPHA had 100% concordance with CDC results, and
low variance between and within runs. At CDC the perfor-
mance of the Abcam kits varied from lot to lot. Three lots
had high sensitivity, whereas the sensitivity was so low in two
lots that the IHPC did not have a positive result in the test,
which invalidated the initial evaluation (Figure 2). It was
notable that the test was still valid according to the criteria.
By switching out the new lot reagents with old lot reagents
one at a time, the problem was identified as low activity of
the biotinylated antibody in the new lot. The kit positive
control (PC) was within the acceptable range in all runs,
leading to the conclusion that the PC was a biotinylated
IgM, which reacted directly with the streptavidin, but which
did not contain CHIKV-specific IgM. CDC reported the prob-
lem to Abcam, which subsequently contacted the original
equipment manufacturer. The components of the kit were
modified so that the biotinylated IgM+ and cutoff controls
were replaced with serum with CHIKV-reactive IgM. These
controls will now only give a positive signal if all the compo-
nents of the sandwich ELISA are working properly. Second,
quality control (QC) of the kits now includes low-positive
serum samples in the evaluation panel; sensitivity of the kit
has to be high enough to detect CHIKV IgM in these low-
positive serum samples for the lot to be validated. In addition,
the suppliers will notify the distributor of any changes made
to the controls or QC process. These changes will allow for
better oversight of the quality of the kits as well as set more
stringent guidelines for the QC process (T von Will, Abcam,
personal communication). Because the kit components were
modified, the initial CDC Abcam kit evaluation and the
CARPHA evaluation were no longer valid, and the refor-
matted kit needed to be reevaluated. Three lots of the kits
containing the CHIKV-specific IgM serum controls were
received and evaluated at CDC and had 99% concordance
(Tables 4 and 6). In the serially diluted samples, the endpoint
of detection in the Abcam ELISA kit ranged from 1:800 to
1:6,400. It is important to note that these results pertain only
to the kit format with the CHIKV-specific IgM serum con-
trols; any further modifications to the kit will invalidate these
results and require reevaluation.
The InBios CHIKjj Detect MAC-ELISA Kit, evaluated at
CDC and CARPHA, had high performance, with 100% and
98% accuracy, respectively. In the serially diluted samples, the
InBios ELISA had the highest sensitivity of all the kits and
equal to that of the CDC MAC-ELISA. Results were highly
concordant with CDC results in replicate testing at CARPHA
to determine within-run, between-run, and between-lot variance
testing, at 100%, 100%, and 98% concordance, respectively.
The Euroimmun IIFT kit, evaluated at CDC and CARPHA,
had high performance (accuracy 96% and 97%, respectively)
but required more retesting of EQ results, due to background
fluorescence from uninfected cells, which could be reduced
somewhat by counterstaining. The proficiency of the techni-
cian also affected the interpretation of results and thus con-
cordance, as side-by-side testing conducted at CARPHAwith
experienced and unexperienced readers showed.
Rapid tests are attractive because they are “low tech” as
they do not need specialized, expensive equipment and do not
require trained, experienced laboratory technicians to run and
interpret the test. They can be performed in a clinical setting,
or at the point of care, so that there is no need to ship the
sample to a laboratory. However, as shown in previous stud-
ies and in this evaluation of the two lateral flow assays with
sensitivities < 50%, rapid tests often lack sensitivity.15,31,32 In
addition, a true negative cannot be distinguished from a false
negative by the validity criteria, because there is no serum
positive control; the assay control only confirms that the
reagents have been applied and the buffer has moved across
the strip and over the detector correctly. Because of the poor
performance of the two rapid tests evaluated at CDC, their
use is not recommended, despite their user-friendly format.
The formats of the CTK and SD CHIKV MAC-ELISA kits
were similar to other assays but had poor performance com-
pared with the CDC MAC-ELISA. Both of these kits lacked
the sensitivity to detect IgM in samples with low, medium, or
high P/N values at CDC.
Commercial manufacturers produce MAC-ELISA kits for
a variety of pathogens. Optimization of the assay for a new
pathogen can be streamlined if most of the reagents remain
the same and are previously standardized, as switching out
reagents may affect performance significantly. In the Abcam kit,
by using a biotinylated IgM PC, only the viral antigen needed
to be changed, which simplified the optimization process.
However, the validity criteria only measured the reactivity of
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the IgM PC with the anti-IgM Mab coated on the plate, not
CHIKV-specific IgM reactivity with the CHIKV antigen. Use
of a virus-specific IgM PC in the kit to measure validity is
essential, as detection of the poor performance of particular
lots of the Abcam ELISA at CDC, which had passed quality
assurance/QC at the manufacturers, demonstrated.
The lot-to-lot variability of the Abcam kit also highlights
the importance of using internal controls at the end-user lab-
oratory. In the Abcam kit evaluation at CDC, without the
inclusion of an IHPC in every run, the invalid runs would
have been considered valid and the true CHIKV IgM+ sam-
ples would have had false-negative results. ELISAs are bio-
logical assays and many factors can have an impact on the
accuracy of the assay. Internal controls help to monitor con-
sistency and detect factors that cause error in testing in addi-
tion to the diagnostic test, such as the equipment, personnel,
and environment. Including an IHPC in each run and
documenting and charting the OD of the IHPC is an essen-
tial component of laboratory QC to assure that the laboratory
results are accurate and the reproducibility of the kit perfor-
mance is reliable.
Specificity was assessed at all three laboratories with
specimens containing IgM to a variety of pathogens or no
pathogen-specific IgM. As expected, there was very little non-
specific reactivity to most of these specimens. CHIKV is an
alphavirus, and inclusion of alphavirus VEEV, EEEV, ONNV,
and MAYV IgM PC serum at CDC and Ross River virus IgM
at NML measured the CHIKV IgM specificity, or alphavirus
cross-reactivity, in the assays. VEEV and EEEV IgM PC
samples had negative results in the CDC MAC-ELISA and
in the four kits. Similarly, the three Ross River virus IgM+
samples included in the NML panel did not react in the
Euroimmun ELISA. MAYV and ONNV IgMs cross-reacted
in the CDC CHIKV MAC-ELISA and showed similar reac-
tivity in the Euroimmun, InBios, and Abcam ELISA kits
(Table 4). Thus, the kits had equal specificity to the refer-
ence tests to VEEV, EEEV, and Ross River virus IgM and
had lack of specificity equal to that of the CDC CHIKV
MAC-ELISA to MAYV and ONNV IgM. MAYV was first
identified on the Island of Trinidad and is known to circulate
in tropical Americas.33 Although large outbreaks of MAYV
have not been reported, sporadic cases of MAYV infection
have been detected.34–36 It is possible, therefore, that a case
of MAYV infection could be misidentified as a CHIKV infec-
tion using the CHIK diagnostic kits without confirmation
by PRNT. ONNV is closely related to CHIKV and cross-
reactivity of antibodies is well described.37,38 A case of ONNV
infection would likely have a positive result in the CHIK diag-
nostic kits.
There were limitations to the evaluations. At CDC the
CHIKV-specific real-time RT-PCR is the first test for sam-
ples collected with the first 6 days of infection. Considered
a confirmatory assay, no samples with positive real-time RT-
PCR results were subsequently tested by MAC-ELISA. The
CARPHA samples were tested at CDC using this testing
algorithm. Similarly, because information on timing of sam-
ple collection was not provided for most samples received at
NML, samples were first tested by MAC-ELISA, and only
those with positive results were tested by real-time RT-PCR.
No samples with negative CHIKV MAC-ELISA results were
tested by real-time RT-PCR. Therefore, with these sample sets
there was no way to assess if any of the commercial IgM
detection assays had higher CHIKV IgM sensitivity than that
of the CDC or NML CHIKV MAC-ELISA, as the panel did
not include samples with positive real-time RT-PCR and neg-
ative CDC or NML MAC-ELISA results. The limited sample
sets of each laboratory in this study illustrate the importance
of establishing and sustaining biobanks for assay assessments
for CHIKV and other rare and emerging viruses.
In summary, the Euroimmun Anti-CHIKV ELISA (IgM),
InBios CHIKjj Detect MAC-ELISA, Abcam Anti-CHIKV
IgM human ELISA (with CHIKV-specific IgM serum con-
trols), and Euroimmun Anti-CHIKV IIFT kits were shown
to have equivalent performance to the reference assays by
which they were evaluated. These commercially available,
validated kits provide laboratories with multiple options for
serological testing for CHIKV infections. Laboratories should
implement QC with an IHPC to ensure the reliability of kit
performance. Any modifications to the kits by the manufac-
turers will necessitate reevaluation.
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